marketing-medtech

**Founder:** Grégoire Paris — Président (directly 30/10/2025, then via his holding Evendale Capital since 30/12/2025)
**Background:** other | verified: False — Unknown / not documented in any real source. The official French registry (RNE via Pappers) confirms only the corporate facts: Grégoire Jean-Louis Paris (born December 1975, age 50) was the founding Président of NEURO IA FRANCE (SAS, SIREN 993267301) on 30/10/2025, then president via his holding company EVENDALE CAPITAL (SIREN 999104615) since 30/12/2025. NEURO IA FRANCE's activity is AI software/application development (NAF 62.01Z); Evendale Capital is a holding/siège social (NAF 70.10Z). No source states his profession, prior career, education, or sector experience. The claimed background category 'other' cannot be substantiated.
**Stage / fundraise:** Pre-product shell / micro-startup: incorporated 27/10/2025, share capital €500, 0 employees, single establishment in Lyon. A live marketing website (neuroiafrance.com) exists with a defined product line. / No fundraising evidence; founder-owned personal holding, not VC-backed.
**Regulatory trigger:** NONE. No medical device, no SaMD, no MDR/CE/IEC 62304 angle. Product is finance/retail business intelligence, which is not a regulated medical pathway.
**Email:** contact@neuroiafrance.com (confidence high) — Published directly on the company website's contact section (also listed phone 09.72.23.27.41). Verified via WebFetch of https://www.neuroiafrance.com/ and curl of the contact page. This is a generic published address, not a personal/founder email.
**LinkedIn:** **Website:** https://www.neuroiafrance.com/
**Score:** 2 -> Tier C
**Hook:** DISQUALIFIED — out of ICP. Despite the "Neuro IA" name and NAF 62.01Z (software dev), the company's actual product is finance/retail business intelligence and ERP, not a SaMD or any digital-health/medical-device product. There is no MDR/IEC 62304/CE pathway, so OmDev's core differentiator (compliance evidence engine for regulated medtech) does not apply, and the company falls outside Damien's medtech-only mandate (fintech is a colleague's territory). No outreach recommended.

---

## Founder & background
Sole named founder: **Grégoire Paris** (born 12/1975). Appointed Président of NEURO IA FRANCE on 30/10/2025, then the presidency passed to his personal holding **EVENDALE CAPITAL** (SASU, SIREN 999104615, NAF 70.10Z holding) on 30/12/2025, of which he is also Président ([Pappers — Neuro IA France](https://www.pappers.fr/entreprise/neuro-ia-france-993267301), [Pappers — Evendale Capital](https://www.pappers.fr/entreprise/evendale-capital-999104615)).
Holding-through-a-personal-SASU is a finance-flavored setup, but no source confirms a finance/insurance career — no LinkedIn match, no bio. The original "investor-backed" read is wrong: Evendale is his own one-man holding, not an external fund. Background classified **other/unknown**.

## Funding & momentum
Incorporated 27/10/2025; share capital **€500**; **0 employees**; single Lyon establishment (16 rue Cuvier, 69006) ([recherche-entreprises](https://recherche-entreprises.api.gouv.fr/search?q=993267301)). No fundraising, grant, or Bpifrance signal found. Owned by a €100 personal holding — no external capital evidenced.

## Product & regulatory
The live site **neuroiafrance.com** shows an **AI finance & retail business-intelligence / "intelligent ERP"** suite (Neuro Forecast, Neuro Pulse, Neuro Orders, Neuro Insights) for SMEs, retail chains and franchises ([neuroiafrance.com](https://www.neuroiafrance.com/)). **No medical device, no SaMD, no MDR/CE/IEC 62304** — zero healthcare angle despite the "Neuro IA" name.

## Pain & buying signals
Genuinely early (0 staff, tiny capital) and could use dev capacity, but the sector is **finance/retail BI**, not medtech. That is outside OmDev's regulated-medtech compliance value prop and outside Damien's medtech-only mandate (fintech belongs to a colleague).

**Why OmDev fits:** It does not. This is a **disqualified, out-of-ICP** lead — no medtech/SaMD product, no regulatory trigger, and the wrong vertical for this outreach track. Recommend dropping it. (Published contact for reference only: contact@neuroiafrance.com.)

---
**Sources:** https://recherche-entreprises.api.gouv.fr/search?q=993267301 · https://www.pappers.fr/entreprise/neuro-ia-france-993267301 · https://www.pappers.fr/entreprise/evendale-capital-999104615 · https://www.neuroiafrance.com/ · https://www.pagesjaunes.fr/siret/99326730100014